Skip to content
DataLookout
Menu

SEEDNCT05786443

Safety and Efficacy of Empagliflozin in Hemodialysis

StatusActive, Not Recruiting
PhasePhase 2
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 9 versions: 8 with changes below, 1 re-verified with no change. See every version on ClinicalTrials.gov ↗

  1. Minor Enrollment closed, study ongoing
    • Site details revised at 2 of 2 sites
  2. Notable Eligibility criteria expanded, about 9 words
    • Secondary endpoints: details revised at 3 of 11 entries
    • Site details revised at 1 of 2 sites
  3. Notable Primary and study completion dates: Dec 30, 2025 to Dec 30, 2026v6
  4. Notable Eligibility criteria shortened, about 2 wordsv5
  5. Notable Trial status: Not Yet Recruiting to Recruiting
    • Start date changed from estimate of Dec 8, 2023 to Jan 31, 2024
    • Site details revised at 2 of 2 sites
    v4
Show 2 earlier versionsHide 2 earlier versions
  1. Notable Start date: Aug 15, 2023 to Dec 8, 2023v3
  2. Notable Start date: Jun 1, 2023 to Aug 15, 2023v2
  1. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Change in Extracellular Volume from Baseline to 12 Weeks
Timeframe: Baseline, Week 12
Change in Intracellular Volume from Baseline to 12 Weeks
Timeframe: Baseline, Week 12
Change in Total Body Water from Baseline to 12 Weeks
Timeframe: Baseline, Week 12
Change in 24-Hour Urine Volume from Baseline to 12 Weeks
Timeframe: Baseline, Week 12

Secondary (11)

Change in 24-Hour Urine Albumin Excretion from Baseline to 12 Weeks
Change in 24-Hour Ambulatory Blood Pressure from Baseline to 12 Weeks
Change in Heart Rate Variability from Baseline to 12 Weeks
Incidence of Intra-Dialytic Hypotension
Incidence of Inter-Dialytic Hypotension
Show 6 moreShow less
Incidence of Serious Hypotension
Incidence of Non-Serious Hypoglycemia
Incidence of Serious Hypoglycemia
Incidence of Ketoacidosis
Number of Adverse Events
Number of Serious Adverse Events

Arms and interventions

EmpagliflozinExperimental

Participants with end-stage kidney disease (ESRD) initiating hemodialysis will receive Empagliflozin 10 mg daily for 12 weeks.

PlaceboPlacebo comparator

Participants with ESRD initiating hemodialysis will receive Empagliflozin-matching placebo daily for 12 weeks.

Drugs: Empagliflozin 10 MG, Placebo

Sites

2 sites in 1 country